Intellia Therapeutics (NASDAQ:NTLA) Hits New 52-Week Low - Time to Sell?

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report)'s stock price hit a new 52-week low during trading on Monday . The company traded as low as $5.90 and last traded at $6.00, with a volume of 517535 shares changing hands. The stock had previously closed at $6.63.

Analysts Set New Price Targets

NTLA has been the subject of several recent analyst reports. Barclays decreased their price objective on shares of Intellia Therapeutics from $55.00 to $26.00 and set an "overweight" rating for the company in a research report on Friday, February 28th. Wedbush reaffirmed a "neutral" rating and set a $10.00 price target (down from $14.00) on shares of Intellia Therapeutics in a report on Friday, January 10th. BMO Capital Markets dropped their price objective on Intellia Therapeutics from $70.00 to $50.00 and set an "outperform" rating on the stock in a report on Friday, January 10th. StockNews.com upgraded Intellia Therapeutics to a "sell" rating in a research note on Monday, March 3rd. Finally, JPMorgan Chase & Co. reiterated a "neutral" rating and issued a $13.00 price target (down from $45.00) on shares of Intellia Therapeutics in a research note on Friday, February 28th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $37.56.

Intellia Therapeutics Trading Up 9.5 %

The stock has a fifty day simple moving average of $9.15 and a two-hundred day simple moving average of $12.59. The company has a market cap of $767.06 million, a PE ratio of -1.36 and a beta of 2.23.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Regeneron Pharmaceuticals Inc. acquired a new position in Intellia Therapeutics during the fourth quarter worth $43,177,000. Voloridge Investment Management LLC raised its stake in shares of Intellia Therapeutics by 226.8% during the 4th quarter. Voloridge Investment Management LLC now owns 1,526,994 shares of the company's stock worth $17,805,000 after buying an additional 1,059,751 shares during the last quarter. Contrarius Group Holdings Ltd purchased a new stake in shares of Intellia Therapeutics in the 4th quarter worth about $11,798,000. Two Sigma Advisers LP grew its stake in Intellia Therapeutics by 94.5% in the 4th quarter. Two Sigma Advisers LP now owns 1,998,317 shares of the company's stock valued at $23,300,000 after acquiring an additional 970,700 shares during the last quarter. Finally, Two Sigma Investments LP increased its holdings in Intellia Therapeutics by 88.1% during the 4th quarter. Two Sigma Investments LP now owns 1,843,743 shares of the company's stock valued at $21,498,000 after acquiring an additional 863,363 shares in the last quarter. Hedge funds and other institutional investors own 88.77% of the company's stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.